- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Jordan Clark | Authors
Articles
Discussing Reimbursement Barriers for FLT3 Mutation Analysis
July 11, 2019
Video
FLT3 mutation analysis in laboratories has brought on reimbursement barriers in clinical oncology. Jordan Clark, chief commercial officer, Diaceutics, a diagnostic development and commercialization company, spoke to Targeted Oncology about the cause of reimbursement issues and how the problem affects all parties involved.